ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

September 13, 2007 14:09 ET

ALDA Pharmaceuticals Appoints New Auditors

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 13, 2007) - ALDA Pharmaceuticals Corp. (the "Company" or "ALDA") (TSX VENTURE:APH) announces that the Company's current auditor, Berris Mangan ("BM"), has resigned as auditor of the Company, effective August 21, 2007, on its own initiative. The Board of Directors has appointed HLB Cinnamon Jang Willoughby Chartered Accountants ("CJW") as the interim auditor of the Company until the annual general meeting. The Company has confirmed that there are no "reportable events" (as such term is defined in National Instrument 51-102 of the Canadian Securities Administrators).

BM is now focusing its practice on TSX-listed companies with Canadian reporting responsibilities.

ALDA is continuing its work towards registration of its securities and reporting in the US and has appointed CJW so that its financial statements may continue to be prepared and audited in accordance with US requirements.

About HLB Cinnamon Jang Willoughby Chartered Accountants

CJW is a member firm of HLB International, a world-wide organization of accounting firms and business advisors with 1,750 partners and over 12,000 staff in 440 offices in over 100 countries. HLB member firms, such as CJW, deal with all sizes of clients and types of assignments, ranging from large publicly listed and public sector clients through to owner-managed, director controlled companies.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp. - Distribution & Sales Contact
    Peter Chen
    CFO and Director
    (604) 521-8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp. - Investor Relations Contact
    Scott Young
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com